Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion

British Journal of Ophthalmology

Volumn 87, Issue 3, 2003, Pages 305-306

  Hvarfner, Charlotte ^a   Hillarp, A ^a   Larsson, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; RETINAL NEOVASCULARIZATION; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037340035     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.3.305     Document Type: Article

References (32)

1. McGrath MA, Wechsler F, Hunyor AB, et al. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978;138:216-20.
2. Ring CP, Pearson TC, Sanders MD, et al. Viscosity and retinal vein thrombosis. Br J Ophthalmol 1976;60:397-410.
3. Elman MJ. Systemic associations af retinal vein occlusion. Int Ophthalmol Clin 1991;31:15-22.
4. Hirota A, Mishima HK, Kiuchi Y. Incidence af retinal vein occlusion at the glaucoma clinic af Hiroshima University. Ophthalmologica 1997;211:288-91.
5. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545-54.
6. Dohlback B. Blood coagulation. Lancet 2000;355:1627-32.
7. Spek CA, Reitsma PH. Genetic risk factors far venous thrombosis. Mol Genet Metab 2000;71:51-61.
8. Greiner K, Hafner G, Dick B, et al. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69-74.
9. Albisinni R, Coppola A, Ioffredo M, et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998;80:702-3.
10. Glueck CJ, Bell H, Vadlamani I, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999;117:43-9.
11. Greiner K, Peetz D, Winkgen A, et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol 1999;23:155-60.
12. Morcucci R, Bertini I, Liotta AA, et al. Activated protein C resistance is a risk factor for central retinal vein occlusion. Ann Ital Med Int 2000;15:195-8.
13. Ciordella AP, Yannuzzi LA, Freund KB, et al. Factor V Leiden, activated protein C resistance, and retinal vein occlusion. Retina 1998;18:308-15.
14. Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 1997;81:832-4.
15. Gottlieb JL, Blice JP, Mestichelli B, et al. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998;116:577-9.
16. Graham SL, Goldberg I, Murray B, et al. Activated protein C resistance - low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust NZ J Ophthalmol 1996;24:199-205.
17. Hodgkins PR, Perry DJ, Sawcer SJ, et al. Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 1995;9:760-2.
18. Linna T, Ylikorkala A, Kontula K, et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997;77:214-6.
19. Raguenes O, Mercier B, Escoffre M, et al.[1691 G to A mutation of the factor V gene: no association with thrombosis of the central retinal vein] Presse Med 1996;25:460.
20. Salomon O, Moisseiev J, Rosenberg N, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 1998;9:617-22.
21. Johnson TM, El Defrawy S, Hodge WG, et al. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina 2001;21:161-6.
22. Scott JA, Arnold JJ, Currie JM, et al. No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. Ophthalmologica 2001;215:217-21.
23. Chan CC, Green WR, Rice TA. Experimental occlusion of the retinal vein. Graefes Arch Clin Exp Ophthalmol 1986;224:507-12.
24. Green WR, Chan CC, Hutchins GM, et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981;79:371-422.
25. Meissner MH, Zierler BK, Bergelin RO, et al. Coagulation, fibrinalysis, and recanalization after acute deep venous thrombosis. J Vasc Surg 2002;35:278-85.
26. The Central Vein Occlusion Study Group N report. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology 1995;102:1434-44.
27. Magargal LE, Brown GC, Augsburger JJ, et al. Neovascular glaucoma following central retinal vein obstruction. Ophthalmology 1981;88:1095-101.
28. Magargal LE, Donoso LA, Sanborn GE. Retinal ischemia and risk af neovascularization following central retinal vein obstruction. Ophthalmology 1982;89:1241-5.
29. Sinclair SH, Gragoudas ES. Prognosis for rubeosis iridis following central retinal vein occlusion. Br J Ophthalmol 1979;63:735-43.
30. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
31. Hayreh SS, Rojas P, Podhajsky P, et al. Ocular neovoscularization with retinal vascular occusion - III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488-506.
32. Quinlan PM, Elman MJ, Bhatt AK, et al. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990;110:118-23.